CB1R antagonists successfully targeted obesity-induced metabolic disease; among them, rimonabant was proven to be a promising treatment in obesity to induce weight loss and improve dyslipidemia [11,25,51,69,70]. The gene discussed is CNR1; the disease is metabolic syndrome.